|Home | About | Journals | Submit | Contact Us | Français|
Nerve growth factor (NGF) was originally discovered as a neurotrophic factor essential for the survival of sensory and sympathetic neurons during development. However in the adult, NGF has been found to play an important role in nociceptor sensitization following tissue injury. Here we outline mechanisms by which NGF activation of its cognate receptor, tropomyosin-related kinase A receptor, regulates a host of ion channels, receptors, and signaling molecules to enhance acute and chronic pain. Further, we document that peripherally restricted antagonism of NGF-tropomyosin-related kinase A receptor signaling is effective for controlling human pain while appearing to maintain normal nociceptor function. Understanding whether there are any unexpected adverse events as well as how humans may change their behavior and use of the injured/degenerating tissue following significant pain relief without sedation will be required to fully appreciate the patient populations that may benefit from these therapies targeting NGF.
Pain is essential for the protective sensibility that enables the avoidance of tissue injury and promotes healing after injury. However, many types of chronic pain become more of a burden than benefit as they have a significant, negative impact on functional status and quality of life. Persistent chronic inflammatory, neuropathic, or cancer pain presents a major health challenge throughout the world.1,2 However, management of chronic pain is often ineffective or incomplete3,4 as current therapies are far from ideal, due in part to a high incidence of dose-limiting side effects4,5. Indeed, there are very few current treatments that effectively control chronic pain without unwanted side effects and/or abuse liability.
International guidelines recommend a multimodal combination of pharmacologic and non-pharmacologic modalities as the most effective strategy to manage the pain and disability associated with chronic pain, where the goal of treatment should be to effectively reduce pain while improving function and reducing suffering.6 Acetaminophen (paracetamol), non-steroidal anti-inflammatory drugs such as ibuprofen and cyclooxygenase-2 inhibitors, and opioids such as tramadol or morphine are the gold standard analgesic drugs in clinical practice. However, concerns regarding the cardiovascular risks of cyclooxygenase-2 inhibitors and the gastrointestinal and renal side effects of non-steroidal anti-inflammatory drugs may limit the use of these medications.7 Where more conservative methods have failed, opioids, appropriately dosed and monitored, are associated with a lower incidence of organ toxicity and fewer potentially life-threatening complications than non-steroidal anti-inflammatory drugs.6,8–10 However, there are a broad spectrum of opioid-mediated side effects and liabilities including loss of effectiveness, constipation (the most common long-term side effect causing non-compliance), drug diversion, respiratory depression and accidental death from overdose.
The effective management of chronic pain can improve patients’ quality of life, functional status, and reduce health care costs.4,11 However, despite significant advances in our understanding of the pathophysiology of chronic pain,12 its management continues to challenge physicians.3 The development of new agents to manage chronic pain, but without significant cardiovascular, gastrointestinal, and central nervous system side-effects, remains a significant, unmet clinical need.
In the present article we present evidence for a new approach to the management of chronic pain that targets the effects elicited by nerve growth factor (NGF). The major objective of this article is to review the science behind targeting NGF or its cognate receptor tropomyosin-related kinase A receptor (TrkA) for the relief of pain, to outline the preclinical and clinical data suggesting that these therapies may be efficacious for relieving several types of chronic pain, and to discuss potential side effects of these therapies. For more detailed and exhaustive scientific discussion of NGF and its receptors, there are several excellent reviews.13–16
NGF belongs to a family of molecules known as neurotrophins, which are approximately 12.5 kD proteins that form tightly bound homodimers. The neurotrophin family of target-derived proteins regulates the survival, development, and function of subsets of sensory and sympathetic neurons.17,18 Other mammalian members of the neurotrophin family are brain derived neurotrophic factor (BDNF), neurotrophin-3 and neurotrophin-4/5. The specificity of action of these molecules is a result of their binding specificity to a family of receptors called tropomyosin-related kinase (Trk) receptors19. TrkA preferentially binds NGF, TrkB binds both BDNF and neurotrophin-4/5, and TrkC binds neurotrophin-3. Neurotrophins also signal via a second receptor called the p75 receptor which binds all neurotrophins, i.e., there is little specificity exerted via the p75 receptor. Trk receptors are often referred to as high affinity receptors in contrast to the low affinity p75 receptor. However, the difference between trk and p75 receptors is not one of affinity but rather kinetics.
NGF binds to TrkA, whereupon the NGF-TrkA complex is internalized and transported from peripheral terminals to sensory cell bodies in the dorsal root ganglion (DRG).20–22 Evidence from several sources suggests that NGF itself cannot initiate signaling in the cell soma, and that instead the NGF-TrkA complex activates transcription factors that control downstream gene expression.21,23 Interactions between p75 and TrkA receptors in determining the response to NGF have been reported24,25. Furthermore, there is evidence that NGF and BDNF can sensitize the discharge of sensory neurons through p75 receptors26,27. However, because this review is directed towards the effects of NGF in enhancing acute and chronic pain in the adult, and Trk antagonists also produce significant relief of chronic pain, in this review we focus on the NGF-TrkA system.
The role of NGF in neuronal development has been known since its discovery nearly 60 years ago.28 NGF plays a critical role in the development of the peripheral nervous system by promoting growth and survival of some neural crest- derived cells in developing embryos, in particular sensory and sympathetic neurons.28,29 An important documentation of these relationships is the fact that selective mutations in NGF or TrkA genes cause congenital insensitivity to pain in humans and loss of pain behaviors in genetically altered mice.30–34 For example, congenital insensitivity to pain with anhidrosis, a human condition in which patients generally have normal proprioception and normal sensation to innocuous pressure but abnormal sensation to thermal stimuli, is caused by a mutation in the TrkA gene35, which results in a structural neuropathy affecting unmyelinated peripheral nerve fibers. Indeed, genetically modified animals lacking the NGF or TrkA gene are born with virtually no small caliber primary sensory neurons, and are correspondingly profoundly unresponsive to noxious stimuli.19,32,33
Studies of NGF deprivation during critical periods of growth support the results of these genetic manipulation experiments. One method of producing long-term NGF deprivation is by immunizing animals to induce autoimmunity against NGF. Such studies reported that NGF is involved in maintenance of sympathetic neurons and the regulation of the substance P (SP) content of embryonic and neonatal sensory neurons.36,37 Immunizing pregnant rats against NGF causes depletion of SP in DRG neurons in those animals exposed in utero or as newborns,38,39 although the regenerative capacity of DRG neurons following axotomy in NGF-immunized animals was unimpaired.37 Anti-NGF antibody administered during early postnatal development in rats has revealed that DRG neurons lose the requirement for NGF for survival shortly after birth, but NGF still has an influence on the phenotype of nociceptors for another 10 days. This was shown by demonstrating that withdrawal of NGF during a critical period led to a developmental switch of high- threshold mechanoreceptors to sensitive mechanoreceptors which normally are relatively rare.40 Importantly, this phenotypic switch of nociceptors occurs in the absence of cell death despite the loss of NGF.41
Collectively, immunologic and genetic studies of NGF deprivation during development and maturation demonstrate that NGF has three separate roles one for survival and development of sensory and sympathetic neurons, the second in maintaining the peptidergic phenotype of primary afferent neurons in the early post-natal period, and the third being a key upstream modulator of the expression and sensitization of a variety of neurotransmitter, receptor and ion channels expressed by adult nociceptors. However, whether adult sensory neurons require NGF for maintenance of their phenotype, if so, how much NGF remains to be determined.
A role for NGF has been demonstrated in both acute, transient nociceptive responses, as well as in longer-term, chronic pain.42–45 As early as 1977, a report that NGF exerts effects on mast cells suggested that the physiologic effects of NGF were not limited to neuronal development and maturation.42 Interestingly, the involvement of NGF in nociception, and the ability of NGF to sensitize nociceptors, only occurs after sensory fibers have lost their dependence on NGF for survival.46 As we discuss below, the NGF-TrkA axis appears to play a pivotal role in the early, intermediate, and long-term generation and maintenance of several types of acute and chronic pain.
An important point in assessing the involvement of the NGF/TrkA pathway in driving a particular chronic pain state is the issue of the specific populations of primary afferent sensory nerve fibers that innervate the injured/diseased tissue. Four broad subtypes of primary sensory neurons have been characterized within the DRG, of which three broad categories are known to be important in nociceptive transmission in the normal animal: thin myelinated Aδ-fibers, peptidergic unmyelinated (C-) fibers, and non-peptidergic unmyelinated (C-) fibers.47 Peptidergic C-fibers and the majority of Aδ-fibers express TrkA, corresponding to approximately 40% of adult DRG cells,48 and are responsive to NGF.47,48 These TrkA-positive fibers innervate skin, viscera, muscle, and bone.49–52 In contrast, non-peptidergic C-fibers (which express c-RET or the binding site for the lectin Griffonia simplicifolia IB4) lack TrkA or p75 and are therefore unresponsive to NGF (TrkA-negative); these fibers innervate skin, but not the skeleton.52–54 These data suggest that a key factor to consider when assessing the analgesic efficacy of targeting NGF-TrkA signaling in an acute or chronic pain state is the fraction of NGF-responsive (TrkA+) nociceptors that innervate the tissue from which the pain is arising, as this innervation and thus the analgesic efficacy of targeting NGF-TrkA signaling may vary considerably from tissue to tissue.
The pivotal role of NGF in inflammatory pain is exemplified by the expression and/or release of NGF by certain inflammatory cells, including eosinophils, lymphocytes, macrophages55,56 and mast cells,57 as a consequence of injury (fig. 1). Moreover, NGF is up-regulated in experimental models of inflammation, including those induced by carrageenan, formalin, and complete Freund’s adjuvant,45,58–60 as well as in models of autoimmune arthritis,61 and ultraviolet B radiation-induced acute inflammation.62 Cutaneous administration of NGF to rodents63 and to humans64 causes hyperalgesia within 1 or 3 hours, respectively, suggesting that NGF leads to a relatively rapid sensitization of cutaneous nociceptors. These rapid effects in the rat are thought to be mediated primarily through NGF binding with TrkA expressed on mast cells, causing degranulation and release of a variety of algogenic mediators, such as histamine, prostaglandin E2, serotonin, hydrogen ions, and bradykinin, as well as additional NGF (fig 1b), although the contribution of mast cells is not as clear in humans. NGF can also be produced by non-inflammatory cells, such as keratinocytes65 and endothelial cells,66 in addition to other inflammatory cells, such as fibroblasts67 and T cells in various in vitro culture models.68
The NGF-induced release of inflammatory mediators from mast cells contributes to the sensitization of polymodal nociceptors. In addition, NGF also binds TrkA receptors expressed on the peptidergic fiber terminal itself (fig. 1), leading to sensitization of primary afferent nociceptors to thermal and chemical stimuli in vitro and in vivo.69,70 This NGF-TrkA activation of intracellular signaling cascades in the primary afferent neurons results in sensitization or increased expression of a number of receptors and channels at the membrane surface, including transient receptor potential vanilloid 1 (TRPV1), acid-sensing ion channels 2 and 3, endothelin receptors, bradykinin receptors, voltage-gated sodium, and calcium channels, delayed rectifier potassium currents and putative mechanotransducers,59,71–73 that contribute to immediate hypersensitivity after inflammation (fig. 1b).
An important mechanism seen within minutes to hours of NGF-TrkA binding is the sensitization of the heat-sensitive ion channel, TRPV1,69,74 expressed by small diameter peptidergic fibers. Acute sensitization of TRPV1 by NGF may involve direct phosphorylation, at least partly due to TrkA-mediated activation of p38 mitogen-activated protein kinases,75 or phosphoinositol kinase 3 and disinhibition following hydrolysis of phosphatidylinositol-4,5-bisphosphate.76,77 Ultimately, sensitization of TRPV1 lowers the temperature threshold of sensory neurons to noxious heat.75–77 Interestingly, however, this does not happen at the level of individual TRPV1 channels recorded in dissociated DRG cells—the inward current response to noxious heat increases as TRPV1 channels are translocated from the interior of the cell to the plasma membrane,78,79 but the temperature threshold does not change.74 Thus any change in temperature threshold of a thermal nociceptor due to NGF-induced sensitization of TRPV1 receptors results from a greater depolarization causing the fiber to reach firing threshold at a lower temperature.
Following the period of immediate hypersensitivity with NGF release after tissue injury, early transcriptional changes occur in the sensory signaling pathway. As NGF principally signals via retrograde transport of the internalized NGF-TrkA complex, there is a delay (from hours to days) before some of NGF’s contribution to hypersensitivity is seen. After retrograde transport to the DRG, the signal from the NGF-TrkA complex can produce changes in sensory phenotype through the switching on (and off) of gene promoters (fig. 2), which leads to increased synthesis of peptides (e.g., SP, calcitonin gene-related peptide [CGRP], and BDNF), and of nociceptor-specific ion channels (NaV1.8, CaV 3.2, 3.3) at the DRG.80–83 For example, exposure of TrkA-positive sensory neurons to NGF elevates expression of the nociceptive acid-sensing ion channel-3 via control of the promoter region of its gene.81 NGF-induced altered gene expression can also lead to a change in phenotype, whereby a population of sensory neurons switches from non-peptidergic to peptidergic and becomes more responsive to NGF.84 Peripheral and dorsal horn terminals of peptidergic fibers express elevated levels of peptides (SP, CGRP and BDNF) as a result of these proteins being packaged and transported retrogradely and anterogradely from the soma (fig. 2).58,83 Indeed, systemic administration of anti-NGF neutralizing antibodies prevents the inflammation-induced up-regulation of neuropeptides (SP, CGRP) and the increased expression of the immediate early gene c-Fos in dorsal horn neurons, without modifying swelling and erythema.60 The peptides, SP and CGRP, may contribute, on subsequent stimulation of the peptidergic primary afferent neurons, to an exaggerated inflammatory response.58,85 In addition, SP itself has been reported to cause local expression of NGF in keratinocytes.86
A delayed phase of the inflammatory response to NGF (7 hours to 4 days after NGF-TrkA binding in rodents), involves an indirect effect of NGF on synaptic transmission between nociceptors and second-order cells in laminae I and II of the spinal cord via its effect on the release of peptides such as BDNF (fig. 2).87 Evidence from 1994 suggested a role for the glutamatergic N-Methyl-D-Aspartate channel, as NGF-induced behavioral hypersensitivity was selectively blocked by the non-competitive N-Methyl-D-Aspartate antagonist, MK-801.45 The N-Methyl-D-Aspartate channel plays a fundamental role in the development of wind-up and central sensitization, mechanisms that are thought to contribute to the development of facilitated sensory signals following injury.88,89 One potential mechanism that is thought to contribute to the development of central sensitization in the dorsal horn is the NGF-dependent upregulation of BDNF in peptidergic nociceptors.90,91 Furthermore, BDNF is transported not only retrogradely to peripheral terminals, but also anterogradely from the DRG to terminals in the dorsal horn (see fig. 2).91–93 BDNF is constitutively expressed in small-and medium-sized DRG neurons, and only released with strong pre-synaptic stimulation.94 Upon release, BDNF acts as a central modulator via post-synaptic TrkB the cognate receptor for BDNF.95,96 BDNF-TrkB binding on second-order cells can activate intracellular protein kinases, which can lead to phosphorylation of glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. This phosphorylation has been shown to contribute to central sensitization at the dorsal horn synapse, particularly in combination with upregulated peptides (SP and CGRP) acting on post-synaptic receptors (fig. 2). BDNF upregulation after peripheral inflammation is NGF dependent, as upregulation is inhibited with administration of anti-NGF antibody.97 Behavioral observations indicate that antagonism of central BDNF attenuates the second (delayed) phase of hyperalgesia induced by formalin and the thermal hyperalgesia induced by carageenan in an NGF-dependent manner, demonstrating a role for BDNF in hypersensitivity and pain.95 Collectively, the data suggest that BDNF-dependent activation of TrkB signaling is required for the development of the central sensitization process that underlies the development of persistent heat and mechanical hypersensitivity in the setting of tissue inflammation or injury.98
These preclinical data point to a fundamental difference between the role of NGF as a factor during growth and differentiation, and its role in the adult sensory system, when NGF-TrkA becomes a major player in the modulation and sensitization of a significant population of nociceptors which are involved in driving chronic pain. As NGF plays a prominent role not only in acute nociception, but in mechanisms behind chronic hypersensitivity, there is a clear scientific rationale for interrupting NGF-TrkA signaling as a target for pain relief therapeutics.
One intriguing but largely unexplored mechanism by which NGF may also generate and maintain hypersensitivity is by inducing aberrant sprouting and/or neuroma formation in response to tissue and/or nerve injury.99–101 In previous studies in a rat model of neuroma, an NGF-sequestering fusion protein reduced both neuroma formation and the spontaneous, ectopic discharge that is a defining characteristic of painful neuromas.100 Other evidence suggests that local administration of NGF to normal peripheral nerves can also induce nerve sprouting of peptidergic (TrkA+) nociceptors.101
NGF activation of TrkA+ has also been demonstrated to induce a remarkable reorganization of sensory and sympathetic nerve fibers. In a mouse model of bone cancer it was shown that when osteosarcoma cells induce a tumor within bone, there is a remarkable sprouting and formation of neuroma-like structures by TrkA+ sensory and sympathetic nerve fibers in the periosteum (fig. 3).102 This sprouting appears to occur within a week that tumor and tumor-associated stromal cells release NGF (fig. 3). Within this week interval these sensory and sympathetic nerve fibers appear to grow more than a millimeter in length and achieve a density never observed in normal bone (fig. 3). Interestingly, sustained administration of an anti-NGF sequestering therapy largely blocked the pathological sprouting of sensory and sympathetic nerve fibers, the formation of neuroma-like structures, and significantly inhibited the generation and maintenance of cancer pain in this model (fig. 3).102
A major issue in interpreting this remarkable and pathological nerve sprouting is the source of the NGF driving this growth? Recent studies using canine prostate cells injected into the mouse bone shed light on the possible source of NGF as these canine prostate cells themselves do not express NGF.103 Following their injection into bone, sclerotic bone lesions similar to that found in human prostate cancer patients are observed and TrkA+ sensory and sympathetic nerve fibers innervating the prostate tumor-bearing bone marrow also undergo a truly remarkable and pathological sprouting.104 As these prostate cells do not express detectable levels of messenger RNA coding for NGF103, these studies suggest that the source of NGF is not the tumor cells themselves but rather NGF released by tumor-associated stromal, inflammatory and immune cells68,105,106 which frequently account for 10–80% of the cells comprising the tumor mass. These data demonstrate that even in the adult bone marrow, NGF released by these inflammatory, immune and stromal cells can induce a 10–70 fold increase in density of TrkA+ sensory nerve fibers in the bone marrow. It should be noted that the phenotype of these newly sprouted nerve fibers may be quite different from nerve fibers that innervate the normal bone and as such these newly sprouted nerve fibers may provide an anatomical substrate which drives skeletal pain. In support of this hypothesis, preventive treatment with an antibody that sequesters NGF, administered when prostate tumor-induced pain and bone remodeling is first observed, blocks the ectopic sprouting and significantly attenuates the development and severity of cancer pain.104
Sprouting of presumptive TrkA+ nerve fibers has also been observed in non-malignant skeletal pain states in both human and animals. For example, prior studies have reported that in humans with chronic discogenic pain there is growth of CGRP+ nerve fibers into normally aneural and avascular areas of the intervertebral disc107. Other studies have demonstrated significant sprouting of CGRP+ nerve fibers following bone fracture in rat and in the arthritic joints of humans and animals108–111. These reports suggest that following injury or disease of the skeleton, significant sprouting of TrkA+ nerve fibers can occur, and it appears that endogenous stromal, inflammatory and immune cells are a major source of NGF68,105,106.
These data on the ectopic sprouting of TrkA+ sensory and sympathetic nerve fibers are interesting as they indicate how pre-emptive treatment with therapies that block NGF activation of TrkA may reduce the attendant pain, but also may block the pathologic remodeling of sensory and sympathetic nerve fibers that are themselves a major driver of chronic hypersensitivity. This might be relevant in situations where one can predict that tissue/nerve injury is about to occur, such as before amputation, orthopedic surgery, or where disease progression is highly likely, such as in osteoarthritis, pancreatic cancer, or tumor metastasis to bone.
A number of strategies have been developed to investigate the role of endogenous NGF in chronic pain. Most commonly, anti-NGF antibodies or a TrkA-IgG fusion protein to sequester NGF have been developed to block the biological activity of NGF. Alternatively, it is possible to prevent NGF binding and activation of TrkA, for example with anti-TrkA antibody or a small molecular inhibitor of TrkA, although NGF activity via p75 will remain intact. These approaches have provided further evidence for the role of NGF in acute and chronic hypersensitivity in adult animals after inflammatory injury.
The systemic administration of anti-NGF antibody has been shown to prevent the acute thermal45,60 and mechanical hyperalgesia induced by complete Freund’s adjuvant,60 while administration of a TrkA-IgG fusion protein minimized behavioral symptoms of hyperalgesia induced by carrageenan112,113 or ultraviolet B radiation.62 Furthermore, although not considered in detail here, it is important to point out that in models of visceral inflammatory pain, hyperalgesia is markedly reduced by pre-treatment with an NGF-neutralizing antibody or TrkA-IgG fusion molecule, for example in acetic acid-induced gastric inflammation,114 trinitrobenzene sulfonic acid-induced colonic hypersensitivity,115 and turpentine or acrolein-induced cystitis.116,117 Furthermore, in a model of colitis, trinitrobenzene sulfonic acid-induced colonic hypersensitivity was also reversed by administering an anti-NGF antibody.115
Antibodies to NGF reversed the established hyperalgesia in a rodent model of autoimmune arthritis,61 suggesting that NGF is involved in prolonged hyperalgesia. Furthermore, the NGF-neutralizing antibody was at least as effective as indomethacin,61 used clinically for relieving arthritis pain. A role for NGF in maintenance of hypersensitivity in chronic injury has also been demonstrated using a model of bone cancer,103,118 and a model of closed femur fracture119,120 (fig. 4). Indeed, anti-NGF produces a profound reduction in both ongoing and movement-evoked bone cancer pain-related behaviors that is greater than that achieved with acute administration of morphine.103,118
Early preclinical experiments modeling long-term NGF deprivation by active immunization of adult animals to auto-produce antibodies against NGF demonstrated a reduction in the number of peripheral DRG fibers compared with untreated controls.121,122 This reduction was selective for unmyelinated C-fibers and was associated with diminished responsiveness to nociceptive stimuli.122 However, in later studies that utilized passive immunization, in which antibodies raised against NGF or TrkA were injected into mature animals, normal nociceptive function remained intact with minimal loss of functional sympathetic or sensory neurons.118,119 Significantly, such anti-NGF antibody treatment reduces pain due to fracture or tumor growth in bone by about 50%,118–120 despite no reduction in the number of peripheral sensory or sympathetic nerve fibers innervating the skin or bone.102,118
One rather unique aspect of the sensory innervation of bone and joint, which may partially explain why anti-NGF therapy is effective in relieving both malignant and non-malignant skeletal pain, is that more than 50% of nerve fibers innervating bone are CGRP+ fibers52, nearly all of which co-express TrkA (fig. 5).123 Accordingly, few unmyelinated non-peptidergic (IB4+/RET+) nerve fibers are present in bone,52–54 and therefore therapies that target NGF or TrkA may be particularly efficacious in relieving bone pain where the tissues are innervated by nociceptors that express TrkA and respond to NGF.
Importantly, preventing NGF-TrkA signaling does not appear to compromise normal physiologic responses to injury, which are critical for effective healing. For example, NGF blockade does not affect the normal inflammatory response (erythema, heat, and swelling).60,113 Furthermore, at least cursory examination of anti-NGF therapy reveals no modification of the biomechanical properties of the femur or histomorphometric indices of bone healing120 and load bearing remains intact although more extensive and exhaustive studies on bone healing are clearly needed. In contrast, in some but not all studies in mouse, rat and humans using various models of bone injury, non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors have been shown to inhibit effective bridging of the fracture site, resulting in delayed bone healing and decreased bone strength.124,125 Also, in a model of bone cancer, neurochemical markers associated with peripheral and central sensitization, such as c-Fos, are reduced on administration of anti-NGF antibody;118 although tumor growth, bone destruction and markers of sensory or sympathetic innervation in the skin are unaffected.
Collectively, the preclinical data suggest that reducing or preventing the NGF production that is associated with some types of injury, through the sequestering of NGF or the inhibition of NGF-TrkA signaling, is effective for reducing hypersensitivity in animal models. Importantly, the studies discussed suggest that, at least at the time points examined, this approach does not obviously compromise normal nociceptor function or cause the loss of sympathetic or sensory nerve fiber innervation of the skin or bone.
In humans, as in animal models, subcutaneous NGF evokes long-lasting mechanical hyperalgesia.126–128 Furthermore, NGF is locally upregulated in humans presenting with chronic pain, such as arthritis, migraine/headache, fibromyalgia, or peripheral nerve injury.129–132 These observations suggest that in humans, as in preclinical animal models, the ongoing production of NGF may be involved in chronic pain and changes in sensitization. Indeed, there are at least three major pharmacologic strategies under development that target NGF-TrkA signaling for the treatment of chronic pain and that have produced effective reduction in hypersensitivity in preclinical models. These are: sequestration of NGF or inhibiting its binding to TrkA;61,133 antagonizing TrkA so as to block NGF from binding to TrkA;134–136 and blocking TrkA kinase activity.137 Among the first such molecules to be investigated pre-clinically were a TrkA-IgG fusion protein,138 as well as MNAC13,134 and PD90780,136 which act by inhibiting the binding of NGF to TrkA and ALE0540135, which appears to act by modulating the interaction of NGF with p75 and indirectly affecting TrkA activation. While several of these molecules showed efficacy in reducing nociceptive behaviors, they were not advanced into clinical trials due to specificity or immunologic response issues. For instance, ALE0540 does not appear to have sufficient selectivity over other tested receptors in vitro, MNAC13 is a mouse monoclonal antibody unsuitable for use in humans and TrkA-IgG contains the extracellular domain of a normal human receptor (TrkA) and therefore is likely to have significant consequences if immunogenicity does develop. This potentially would be similar to the problems seen in rare patients treated with recombinant analogues of erythropoetin when they became autoimmune to their endogenous erythropoietin.139 In contrast, a number of humanized anti-NGF monoclonal antibodies—RN624 (tanezumab), JNJ-42160443, REGN475, PG110, Alpha-D11, AMG-403, which exert their analgesic effect by sequestering endogenous NGF — are currently being investigated in clinical trials in patients with various types of chronic non-cancer pain133,140. The outcomes of these clinical trials will provide key information on the efficacy of anti-NGF antibody therapy for the relief of pain in patients with different forms of chronic pain. Importantly, in studies published to date, and in line with preclinical studies, anti-NGF therapy appears to be anti-hyperalgesic (i.e. normalizing a decreased nociceptive threshold) as opposed to analgesic (i.e. increasing normal and sensitized nociceptive threshold). Long-term studies are required to enable a comparison of the safety profile of anti-NGF antibody therapy with those of currently used analgesic agents for chronic non-cancer pain, where adverse side effects include gastrointestinal problems and potential cardiovascular risks. In addition, the safety profile of anti-NGF therapies must be investigated in a range of patients with different types of chronic pain.
Ultimately, the utility of NGF antagonism for pain relief in humans will depend on the contribution of the various NGF signaling pathways to the specific chronic pain condition. It is likely that not all types of pain are effectively reversed by antagonizing NGF-TrkA signaling. This therapeutic approach clearly relies on NGF being an important driver of the increased pain sensitivity; if other factors are responsible for driving the hyperalgesic state, inhibition of NGF may not be effective. For example, target- derived NGF is lost under conditions such as diabetes where peripheral fibers suffer damage, a condition often accompanied by pain. Here, NGF might be expected to improve regeneration141,142 thereby reducing pain. However, this approach was abandoned in patients with diabetic peripheral neuropathy due to dose-limiting painful side effects.143
NGF may be primarily involved in the initiation of changes that lead to chronic pain, and may not itself have a prominent role in maintenance of hypersensitivity. Therefore, the stage at which NGF is important in the development of ongoing hypersensitivity needs to be defined. Moreover, the extent to which signaling pathways are interlinked may limit their use clinically as well as in the interpretation of preclinical results. For example, anti-TrkA antibodies should suppress TrkA signaling, but they may also affect p75 signaling since there is speculation that the two pathways interact.144 Furthermore, specific nociceptor innervation of each tissue may influence the efficacy of NGF-TrkA blocking strategies. Preclinical investigators who have focused on skeletal pain have proposed that anti-NGF treatment may be particularly effective in pain that originates in bone,102–104,118,119,145 around 80% of the myelinated and unmyelinated nerve fibers that innervate the bone are responsive to NGF.123
In order to optimize the therapeutic potential of NGF inhibitors, further research is needed to establish which types of human chronic pain are driven by, and more importantly, maintained by NGF. It is also important to understand when in the disease process NGF antagonism is most effective. For example, the pain that immediately follows bone fracture (from seconds to minutes later) is not inhibited by treatment with anti-NGF antibody in preclinical studies, whereas 24 hours following fracture anti-NGF therapy reduced bone fracture pain by >50% (fig. 4).119,120 This may indicate that initial nociceptive signals are driven by activation of, for example, mechanotransducers, independent of NGF, whereas secondary nociception that occurs hours to days after fracture may be increased by the release of NGF contributing to activation and sensitization of nociceptors.120 Further study is also required to evaluate the putative effects of anti-NGF on other disease processes, such as weight loss in autoimmune arthritis61 and bone loss in the chronic pain condition known as complex regional pain syndrome I.146
In addition to defining the analgesic efficacy of blocking the NGF-TrkA axis, key safety issues which need to be addressed with any therapy targeting NGF or TrkA include effects on normal autonomic and sensory neuron structure and function; physiological responses to injury, wound healing and endocrine function; ability to cross placental or blood–brain-barrier in the normal or injured state, and thus any influence on central nervous system neurons such as the basal forebrain cholinergic neurons that are sensitive to NGF. Additionally, given that bone pain may be a major target for NGF-TrkA therapies, understanding how these therapies effect individuals that have advanced bone degeneration will be critical. Indeed, recent human clinical trials in elderly humans with osteoarthritis have been halted due to the need for earlier than expected joint replacement in a small subset of patients.140 Whether this earlier than expected joint replacement in patients being treated with anti-NGF is simply due to greater use of the diseased joint or to unforeseen adverse events on the biomechanical properties of bone itself remains a critical but as yet unanswered question. These data emphasize the need to clearly understand not only the analgesic efficacy of TrkA-NGF blocking therapies and any unexpected effects but how patients with chronic pain change their behavior and use of the injured/degenerating tissue following administration of a therapy that provides significant pain relief without sedation.
This review provides an overview of the mechanisms by which NGF drives acute and chronic pain in the adult, and outlines how NGF has a distinct role in the adult as compared with the developing nervous system. To date, therapies that target NGF-TrkA-signaling have shown significant analgesic efficacy in both animals and humans in several difficult-to-treat chronic pain states. In choosing which chronic pain states to target with NGF-TrkA therapies, a key issue to consider is the fraction of NGF-responsive (TrkA+) nociceptors that innervate the tissue from which the pain is arising, as this innervation varies considerably from tissue to tissue. If successful, therapies that target NGF-TrkA signaling represent a new class of analgesic therapy that have the potential to profoundly change the therapeutic landscape of how we treat several types of chronic pain.
Editorial support was provided by Karen Burrows, MPhil (Senior Medical Writer), and Aideen Young, PhD (Senior Medical Writer), of UBC Scientific Solutions, Ltd., Horsham, UK, and funded by Pfizer Inc, New York, NY.
Conflict of interest: Karen Burrow and Aideen Young wrote the first rough draft of the manuscript in September 2009. Patrick Mantyh (PM), Martin Koltzenburg (MK), Lorne Mendell (LM), David Shelton (DS) and Leslie Tive (LT) then extensively edited and rewrote the manuscript in 20 separate drafts during the next 12 months. PM served as the lead author in rewriting, deleting, and adding new material and sections to the manuscript. PM drew the rough outlines of the figures which were then redrawn in professional format by Annemarie Johnson at Wake Forest University. PM, MK and LM are responsible for the views and opinions of this manuscript and did not receive any fees eror compensation for the writing of this review.
Author disclosure information: Dr. Mantyh is supported by the National Institutes of Health grant (NS23970, Bethesda, MD) and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Grants (O4380-I and A6707-R, Washington, DC). Dr. Mantyh received anti-nerve growth factor as a research tool and gift from Rinat Laboratories, Pfizer Inc (South San Francisco, CA) and has served as a consultant and has had research grants from Abbott (Abbott Park, IL), Adolor (Exton, PA), Array Biopharma (Boulder, CO), Johnson and Johnson (New Brunswick, NJ), Pfizer (New York, NY), Plexxikon (Berkeley, CA) and Roche (South San Francisco, CA).
Dr. Koltzenburg is currently supported by the Brain Research Trust (London WC1A 2AJ, United Kingdom), the Department of Health’s Comprehensive Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust (London W1T 7NF, United Kingdom) and the Medical Research Council (London, WC2B 4AN, United Kingdom). In the past 3 years he has served as consultant for AstraZeneca (Sodertalje, Sweden), Endo (Chadds Ford, PA), Johnson and Johnson (New Brunswick, NJ), Grunenthal (Aachen, Germany), Merck (Whitehouse Station, NJ), Novartis Pharmaceuticals UK (Horsham, United Kingdom) Organon (Oss, The Netherlands), Quintiles (Durham, NC), Pfizer (New York, NY), QRX Pharma (Bedminster, NJ) and Schering-Plough (Kenilworth, NJ).
Dr. Mendell is supported by the NIH (grant number 5RO1 NS 16996, Bethesda, MD), the Christopher and Dana Reeve Foundation (LMC- 2010, Short Hills, NJ), and the William Heiser Foundation (Wantagh, NY). His neurotrophin research has been aided by gifts of brain-derived nerve growth factor and neurotrophin-3 from Regeneron Pharmaceuticals Inc (Tarrytown, NY), and nerve growth factor and neurotrophin-4/5 from Genentech, Inc (South San Francisco, CA) for whom he has also consulted. He has also consulted for Pfizer, Inc (New York, NY).
Dr. Tive is an employee of Pfizer Inc.
Dr. Shelton is an employee of Rinat Laboratories, Pfizer Inc.